When a global pharmaceutical company received a request to share data from a 5+ year-old observational study, they turned to Instem and its Blur™ platform to tackle the complex challenge of de-identifying legacy data stored in a proprietary format. With over 60,000 variables spread across multiple datasets, the project far exceeded the typical scope of clinical trial transparency projects brought to Instem. In order to combat this challenge, Instem leveraged Blur’s advanced anonymization and risk assessment capabilities to deliver clean, compliant, and shareable data in just one month.
Complete the form to download the case study to explore how Blur™ enabled secure, efficient data sharing while protecting patient privacy and supporting clinical transparency.